

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	10/747,686		
		Filing Date	December 30, 2003		
		First Named Inventor	STEINER, Mitchell S.		
		Group Art Unit	1615		
Examiner Name	Fubara, Blessing M				
Sheet	1	of	10	Attorney Docket Number	P-2769-US9

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BF	A	4,990,538		Harris et al.	February 5, 91	
	B	5,788,964		Baral et al.	August 4, 98	
	C	5,650,425		Biegnon et al.	July 22, 97	
	D	4,696,949		Toivola et al.	Sept 29, 87	
	E	5,491,173		Toivola et al.	Feb. 13, 1996	
	F	5,571,534		Jalonen et al.	Nov. 5, 1996	
	G	5,605,700		DeGregorio et al.	Feb. 25, 1997	
	H	5,595,722		Grainger et al.	Jan. 21, 1997	
	I	5,599,844		Grainger et al.	Feb. 4, 1997	
	J	5,629,007		Audia et al.	May 13, 1997	
	K	5,635,197		Audia et al.	June 3, 1997	
BF	L	5,595,985		Labric	Jan. 21, 1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
BF	M	WO	98/58634		DEGREGORIO, et al	December 30, 98		
	N	EP	415 623 A2		Harris et al	March 6, 1991		
	O	EP	616 529 B1			September 28, 94		
	P	EPC	095875			Dec 7, 1995		
	Q	WO	95/26720		Biegon et al	Oct 12, 1995		
BF	R	WO	0008001		Huebner, et al	Feb 17, 2000		

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/747,686
				Filing Date	December 30, 2003
				First Named Inventor	STEINER, Mitchell S.
				Group Art Unit	1615
				Examiner Name	Fubara, Blessing M
Sheet	2	of	10	Attorney Docket Number	P-2769-US9

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BF	S	4,329,364		Neri et al.	May 11, 1982	
	T	4,474,813		Neri et al.	Oct. 2, 1984	
	U	6,080,877		Swindell et al	June, 2000	
	V	6,265,448		Steiner et al	July 24, 2001	
	W	6,410,043		Steiner et al	June 25, 2002	
	X	6,632,447		Steiner et al	Oct 14, 2003	
	Y	6,413,533		Steiner et al	July 2, 2002	
	Z	6,413,534		Steiner et al	July 2, 2002	
	AA	6,413,535		Steiner et al	July 2, 2002	
	AB	4,996,225		Toivola et al	Feb 26, 1991	
	AC	5,811,120		Gibson et al	Sept 22, 1998	
	AD	5,972,383		Gibson et al	Oct 26, 1999	
BF	AE	4,418,068		Jones	Nov 29, 1983	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
BF	AF	WO	94/12162		Warri et al	June 9, 1994		<input type="checkbox"/>
BF	AG	WO	99/56739		Steiner et al	November 11, 1999		<input type="checkbox"/>
BF	AH	WO	00/47214		Healey et al	August 17, 2000		<input type="checkbox"/>
BF	AI	WO	96/09046		Audia et al	March 28, 1996		<input type="checkbox"/>
BF	AJ	EP	0 670 162		Gibson et al	Sept 6, 1995		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/747,686
				Filing Date	December 30, 2003
				First Named Inventor	STEINER, Mitchell S.
				Group Art Unit	1615
				Examiner Name	Fubara, Blessing M
Sheet	3	of	10	Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF	AK	Brawley et al., "Chemoprevention of Prostate Cancer" in Urology, 1994, Vol. 43, No. 5.	<input type="checkbox"/>
	AL	Christian Rohlf et al. "Prostate Cancer Cell Growth Inhibition by Tamoxifen Is Associated With Inhibition of Protein Linase C and Induction of p21" The Prostate 37:51-59 (1998) ©1998 Wiley-Liss, Inc	<input type="checkbox"/>
	AM	Gershanovich et al., "A Phase III Comparison of Two Toremifene Doses to Tamoxifen in Postmenopausal Women with Advanced Breast Cancer", Breast Cancer Research and Treatment 45, 1997, Pages 251-262.	
	AN	Gingrich et al., "Androgen-independent Prostate Cancer Progression in the TRAMP Model", in Cancer Research 57, November 1, 1997, pages 4687-4691.	
	AO	Gingrich et al., "Metastatic Prostrate Cancer in a Transgenic Mouse", in Cancer Research 56, September 15, 1996, pages 4096-4102.	
	AP	Gingrich et al., "Pathologic Progression of Autochthonous Prostate Cancer in the TRAMP Model", Prostate Cancer and Prostatic Diseases, 1999, 2, Pages 70-75.	
	AQ	Greenwald "Expanding Horizons in Breast and Prostate Cancer Prevention and Early Detection", in J. Cancer Education, 1993, Vol. 8, No. 2, pages 91-107.	<input type="checkbox"/>
	AR	Kelloff et al., "Introductory Remarks: Development of Chemopreventive Agents for Prostate Cancer" in Journal of Cellular Biochemistry, 1992, Supplement 16H: 1-8.	<input type="checkbox"/>
	AS	Lucia et al., "Chemopreventive Activity of Tamoxifen, N-(4-Hydroxyphenyl)retinamide, and the Vitamin D Analogue Ro24-553 1 for Androgen-promoted Carcinomas of the Rat Seminal Vesicle and Prostate" in Cancer Research, 1995, vol. 55, pages 5621-5627.	<input type="checkbox"/>
	AT	Martel Celine et al. "Binding Characteristics of Novel Nonsteroidal Antiestrogens to the Rat Uterine Estrogen Receptors", Pergamon, J. Steroid Biochem. Molec. Bio. Vol 64, No. 3-4, pp. 199-205, 1998.	<input type="checkbox"/>
	AU	Nevalanine et al. "Hormone Regulation of Human Prostate in Organ Culture" Cancer Res., vol. 53, no. 21, 1993, pages 5199-5207, XO002117653.	<input type="checkbox"/>
	AV	Potter et al., "A Mechanistic Hypothesis for DNA Adduct Formation By Tamoxifen Following Hepatic Oxidative Metabolism" in Carcinogenesis, 1994, Vol. 15, No. 3, pages 439-442.	<input type="checkbox"/>
	AW	Richard Gams, MD "Phase III Trials of Toremifene vs Tamoxifen" Oncology Volume 11, Number 5, Supplement 4, May 1997	<input type="checkbox"/>
✓	AX	Schneider Martin R. et al. "Nonsteroidal Antiestrogens and Partial Estrogens with Prostatic Tumor Inhibiting Activity", Cancer Research Clinical Oncology. Springer-Verlag 1986, J Cancer Res Clin Oncol (1986) 112: 258-265, p. 258-265,	<input type="checkbox"/>
BF	AY	Valavaara Ritva, MD, PhD "Reliability of Estrogen Receptors in Predicting Response To Antiestrogens", Oncology, Volume 11 Number 5 Supplement No. 4 p. 14-18.	<input type="checkbox"/>

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Fubara, Blessing M
		Attorney Docket Number	P-2769-US9
Sheet	4 of 10		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF	AZ	Black et al. "Uterine Bioassay of Tamoxifen, Trioxifene and a New Estrogen Antagonist (LY117018) in Rats and Mice" in Life Sciences, 1980, Vol. 26, pp. 1453-1458	
	BA	Greenwald et al. "Breast Cancer Prevention and Early Detection", pages 93-106.	
	BB	Hayes et al. "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, Vol. 13, No. 10, 1995, pages 2556-2566.	
	BC	Hietanen T "Open Phase II Study of High-Dose Toremifene as First-Line Therapy for Advanced Breast Cancer" in Oncology - May 1997; 11(5 Suppl 4): 37-40.	
	BD	Jordan VC "Toremifene As An Anticancer Agent", Cancer Invest 1990; 8(2) 271	
	BE	Karlsson S. et al. "A Two-Year Dietary Carcinogenicity Study Of The Antiestrogen Toremifene In Sprague-Dawley Rats" Drug Chem Toxicol 1996 Nov; 19(4): 245-66.	
	BF	Moon RC et al. "Chemoprevention of MNU-Induced Mammary Tumorigenesis by Hormone Response Modifiers: Toremifene, RU 16117, Tamoxifen, Aminoglutethimide and Progesterone", Anticancer Res 1994 May-June; 14(3A): 889-93.	
	BG	Moore et al. "Regulation of Cytoplasmic Dihydrotestosterone Binding in Dog Prostate by 17β-Estadiol", in J. Clin. Invest. © The American Society for Clinical Investigation, Inc., Vol. 63 March 1979, pages 351-357.	
	BH	Neubauer et al., "Endocrine and Antiprostatic Effects of Raloxifene (LY156758) in the Male Rat", The Prostate 23, 1993, pages 245-262.	
	BI	Perry "High Dose Toremifene for Estrogen and Progesterone Receptor Negative Metastatic Breast Cancer: a Phase II Trial of the Cancer and Leukemia Group B (CALGB)", in Breast Cancer Res Treat - 1995; 26(1): 25-40	
	BJ	Pollard, "Prevention of Prostate-Related Cancers in Lobund-Wistar Rats", The Prostate 39, 1999, pages 305-309.	
	BK	Powles TJ "Status Of Antiestrogen Breast Cancer Prevention Trials" Oncology (Huntingt) 1998 Mar; 12(3 Suppl 5): 28-31.	
	BL	Pyrhonen et al., "Comparison of Toremifene and Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer: a Randomized Double-blind, the 'Nordic' Phase III Study", British Journal of Cancer, 1997, 76(2), pages 270-277.	
	BM	Shenfeld et al. "Androgen Deprivation Therapy", Chapter 37, Section III/Prostate Cancer, pages 467-477	
	BN	Shirai et al. "Effects of Testosterone, Dihydrotestosterone and Estrogen on 3,2'-Dimethyl-4-Aminobiphenyl-Induced Rat Prostate Carcinogenesis" in Int. J Cancer: 57, 224-228 (1994)	
BF	BO	Simard et al., "Keoxifene Shows Pure Antiestrogenic Activity in Pituitary Gonadotrophs", Molecular and Cellular Endocrinology 39, 1985, pages 141-144.	

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Fubara, Blessing M
(use as many sheets as necessary)		Attorney Docket Number	P-2769-US9
Sheet	5 of 10		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF	BP	"Chemoprevention Of Prostate Cancer: Guidelines For Possible Intervention Strategies", <i>Journal of Cellular Biochemistry</i> , Supplement 16H:140-145 (1992).	
	BQ	Awoniyi Caleb A. et al. "Neonatal Exposure To Coumestrol, A Phytostrogen, Does Not Alter Spermatogenic Potential In Rats", <i>Endocrine</i> , vol. 7, no. 3, 337-341, December 1997.	
	BR	Bergan RC et al. "A Phase II Study Of High-Dose Tamoxifen In Patients With Hormone-Refractory Prostate Cancer." <i>Clin Cancer Res</i> 1999 Sep; 5(9): 2366-73.	
	BS	Brandes LJ et al. "Salutary Clinical Response Of Prostate Cancer To Antiandrogen Withdrawal: Assessment Of Flutamide In An In Vitro Paradigm Predictive Of Tumor Growth Enhancement", <i>Clin Cancer Res</i> 1997 Aug; 3(8): 1357-61.	
	BT	Chang William Y et al. "Estrogen Receptor-β: Implications For The Prostate Gland" <i>The Prostate</i> 40:115-124 (1999)	
	BU	Foekens JA et al. "Expression Of Prostate-Specific Antigen (PSA) Correlates With Poor Response To Tamoxifen Therapy In Recurrent Breast Cancer", <i>Br J Cancer</i> 1999 Feb; 79(5-6): 888-94.	
	BV	Hempstock J. et al. "Growth Inhibition Of Prostate Cell Lines In Vitro By Phyto-Oestrogens", <i>British Journal Of Urology</i> (1998). 82. 560-563.	
	BW	Lippman SM et al. "Cancer Chemoprevention", <i>J Clin Oncol</i> 1994 Apr; 12(4):851-73.	
	BX	Miyata E et al. "Effects Of Tamoxifen, An Antiestrogen, On Rat Prostate Carcinogenesis by 3,2'-Dimethyl-4-Aminobiphenyl And Testosterone Do Not Support An Estrogen Role In Testosterone Promotion", <i>Prostate</i> 1997 Apr 1;31(1)9-13.	
	BY	Nevalainen MT et al. "Expression and Hormone Regulation Of Prolactin Receptors in Rat Dorsal and Lateral Prostate", <i>Endocrinology</i> 1996 Jul; 137(7): 3078-88.	
	BZ	Pienta KJ et al. "A Phase II Evaluation Of Oral Tamoxifen And Intermittent Intravenous Vinblastine In Hormone-Refractory Adenocarcinoma Of The Prostate"., <i>Am J Clin Oncol</i> 1996 Oct; 19(5):500-3.	
	CA	Pienta KJ et al. "Inhibition Of Prostate Cancer Growth By Vinblastine And Tamoxifen", <i>Prostate</i> 1995 May; 26(5): 270-4.	
	CB	Prins Gail S. et al, "Neonatal Estrogen Exposure Up-Regulates Estrogen Receptor Expression In The Developing And Adult Rat Prostate Lobes*", <i>Endocrinology</i> 138: 1801-1809, 1997)	
	CC	Shughrue Paul J. et al. "Comparative Distribution Of Estrogen Receptor-α (Er-α) And β (Er-β) mRNA In The Rat Pituitary, Gonad, And Reproductive Tract" <i>Steroids</i> 63: 498-504, 1998, Elsevier Science Inc.	
BF	CD	Szarka CE et al. "Chemoprevention Of Cancer", <i>Curr Probl Cancer</i> 1994 Jan-Feb; 18(1):6-79.	

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/747,686
				Filing Date	December 30, 2003
				First Named Inventor	STEINER, Mitchell S.
				Group Art Unit	1615
				Examiner Name	Fubara, Blessing M
Sheet	6	of	10	Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
BP	CE	"Editorial: A New Actor In The Estrogen Receptor Drama-Entre ER-β", Endocrinology Vol. 138, No. 3, (1997).		
	CF	"When Is Intervention Warranted?", Journal Of Cellular Biochemistry, Supplement 16H:138-139 (1992).		
	CG	Anttila M et al. "Pharmacokinetics Of The Novel Antiestrogenic Agent Toremifene In Subjects With Altered Liver And Kidney Function" Clin Pharmacol Ther 1995 Jun; 57(6):628-35.		
	CH	Colletta Anthony A. et al. "Alternative Mechanisms Of Action Of Anti-Oestrogens" Breast Cancer Research and Treatment 31: 5-9, 1994.		
	CI	Fleton SA "Potential New Antiestrogens For The Treatment Of Breast Cancer", Highlights in Oncology Practice Vol. 15, No. 2, 1997 p. 47-52		
	CJ	Griffiths K. et al. "Further Insights Into Endocrine Disease - Diet and Prostate Disease" An IPHC Teaching Programme.		
	CK	Horton J et al. "Tamoxifen In Advanced Prostate Cancer: An ECOG Pilot Study", Prostate 1988; 12(2):173-7.		
	CL	Kamat AM et al. "Chemoprevention Of Urological Cancer", The Journal Of Urology, Vol. 161. 1748-1760. June 1999, p. 1748-1760.		
	CM	Kangas L "Development And Biochemical Pharmacology Of Toremifene, An Antiestrogenic Antitumor Drug", Acta Obstet Gynecol Scand 1991; 70(4-5): 399.		
	CN	Kuiper George G. J. M. et al. "Comparison Of The Ligand Binding Specificity And Transcript Tissue Distribution Of Estrogen Receptors α and β", Endocrinology Vol. 138, No. 3, 863-870 (1997).		
	CO	Moon R.C. et al. "Chemoprevention of MNU-Induced Mammary Tumorigenesis by Hormone Response Modifiers: Toremifene, RU 16117, Tamoxifen, Aminoglutethimide and Progesterone", Anticancer Research 14: 889-894 (1994)		
	CP	Nevalainen M.T. et al. "Estrogen and Prolactin Regulation of Rat Dorsal and Lateral Prostate in Organ Culture", Endocrinology, Vol. 129, No. 2 pages 612-618		
↓	CQ	Price K. R. et al. "Naturally Occurring Oestrogens in Food - A review", Food Additives and Contaminants, 1985, Vol. 2, No. 2, 73-106.		
BP	CR	Yu H et al. "Induction Of Prostate Specific Antigen Production By Steroids And Taxoxifen In Breast Cancer Cell Lines", Breast Cancer Res Treat 1994; 32(3)291-300.		

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/747,686
				Filing Date	December 30, 2003
				First Named Inventor	STEINER, Mitchell S.
				Group Art Unit	1615
				Examiner Name	Fubara, Blessing M
Sheet	7	of	10	Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF	CS	"New Research Approaches In The Prevention And Cure Of Prostate Cancer", American Association For Cancer Research. December 1998	
	CT	Boehm S et al. "Estrogen Suppression As A Pharmacotherapeutic Strategy In The Medical Treatment Of Benign Prostatic Hyperplasia: Evidence For Its Efficacy From Studies With Mepartricin" Wien Klin Wochenschr 1998 Dec 11; 110(23):817-23.	
	CU	Bonkhoff H et al. "Estrogen Receptor Expression In Prostate Cancer and Premalignant Prostatic Lesions", American Journal of Pathology, Vol. 155, No. 2 August 1999.	
	CV	Buelke-Sam J. et al. "The Selective Estrogen Receptor Modulator, Raloxifene: An Overview Of NonClinical Pharmacology And Reproductive And Developmental Testing", Reprod Toxicol 1998 May-June; 12(3):217-21.	
	CW	Cheng E et al. "Endocrinology Of The Prostate", Prostate Diseases, chapter 5- p. 57-71.	
	CX	Dhar JD et al. "Estrogen, Androgen and Antiestrogen Responses In The Accessory Organs Of Male Rats During Different Phases Of Life", Endocr Res 1998 May; 24(2): 159-69.	
	CY	Landstrom M, et al. "Inhibitory Effects Of Soy and Rye Diets On The Development Of Dunning R3327 Prostate Adenocarcinoma in Rats, The Prostate 36: 151-161 (1998).	
	CZ	Strauss L "Genistein Exerts Estrogen-Like Effects In Male Mouse Reproductive Tract", Molecular and Cellular Endocrinology 144 (1998) 83-93, Elsevier Science Ireland Ltd.	
	DA	Treinen KA et al. "An Evaluation Of The Novel Selective Estrogen Receptor Modulator, Idoxifene, For Effects On Reproduction In Rats And Rabbits:, Toxicol Sci 1998 Feb; 41(2):199-207.	
↓	DB	West Neal B et al. "Estrogen and Progestin Receptors And Aromatase Activity In Rhesus Monkey Prostate" Endocrinology, Vol. L. 123, (1998)	
BF	DC	Xiaolin Zi et al. "Silibinin Decreases Prostate-Specific Antigen With Cell Growth Inhibition Via G1 Arrest, Leading To Differentiation Of Prostate Carcinoma Cells: Implications For Prostate Cancer Intervention:, Proc. Natl. Acad. Sci, USA Vol. 96, pp. 7490-7495, June 1999. Medical Sciences.	

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/747,686
				Filing Date	December 30, 2003
				First Named Inventor	STEINER, Mitchell S.
				Group Art Unit	1615
				Examiner Name	Fubara, Blessing M
Sheet	8	of	10	Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF	DD	Albert David S. et al. "An Overview Of Clinical Cancer Chemoprevention Studies With Emphasis On Positive Phase III Studies" Overview of Diet Cancer 6928-6975 (1995)	
	DE	Buelke-Sam Judy et al. "The Selective Estrogen Receptor Modulator, Raloxifene: An Overview Of NonClinical Pharmacology and Reproductive Development Testing", Reproductive Toxicology Vol. 12, No. 3 pp. 217-221, 1998.	
	DF	Hayes "A Randomized Comparison Of Tamoxifen, Trioxifene And A New Estrogen Antagonist (LY117018) In Rats And Mice" In Life Sciences, 1980, vol. 26, pp. 1453-1458.	
	DG	Hobisch Alfred "Metastatic Lesions From Prostate Cancer Do Not Express Oestrogen And Progesterone Receptors" J. Pathol. 182: 356-361, 1997.	
	DH	Horton John et al. "Tamoxifen In Advanced Prostate Cancer" An ECOG Pilot Study", The Prostate 12: 173-177 (1988).	
	DI	Jordan Craig V. "Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow" Journal of National Cancer Institute, Vol. 90, No. 13, July 1, 1998	
	DJ	Kellof GJ et al.. "Strategies For Chemoprevention Of Prostate Cancer", Prostate Cancer and Prostate Disease (1988) 5. 107.	
	DK	Kuiper George G. J. M. "Cloning Of A Novel Estrogen Receptor Expressed In Rat Prostate And Ovary", Proc. Natl. Acad. Sci USA Vol. 93, pp. 5925-5930, June 1996 Biochemistry.	
	DL	Kuiper George G. J. M. "Interaction Of Estrogenic Chemicals and Phytoestrogens With Estrogen Receptor β ", Endocrinology Vol. 139, No. 10 (1998).	
	DM	Mobbs, B.G. et al "Concentration and Cellular Distribution of Androgen Receptor in Human Prostatic Neoplasia: Can Estrogen Treatment Increase Androgen Receptor Content?" J. Steroid Biochem. Vol. 19, No. 3 pp. 1279-1290, 1983.	
	DN	Prins Gail S. "Developmental Estrogenization Of The Prostate Gland", Prostate: Basic and Clinical Aspects p. 245-263 (1997).	
	DO	Strom Sara S. et al. "Phytoestrogen Intake and Prostate Cancer: A Case-Control Study Using A New Database", Nutrition and Cancer, 33(1), 20-25. (1999).	
BF	DP	Warri Anni. M. et al "Apoptosis in Toremifene Induced Growth Inhibition of Human Breast Cancer Cells in Vivo and In Vitro" Journal of National Cancer Institute, Vol. 85, No. 17, September 1, 1993	

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/747,686
		Filing Date	December 30, 2003
		First Named Inventor	STEINER, Mitchell S.
		Group Art Unit	1615
		Examiner Name	Fubara, Blessing M
(use as many sheets as necessary)		Attorney Docket Number	P-2769-US9
Sheet	9	of	10

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NEW FROM HERE	DQ	"GTx begins next phase of clinical trials for prostate cancer." Expert Rev Anticancer Ther. 2001 1(3) 326	
BF	DR	Bostwick David "Prospective Origins of Prostate Carcinoma" American Cancer Society 1996	
	DS	Bostwick, David G. et al "Reversibility of Prostatic Intraepithelial Neoplasia: Implications for Chemoprevention" Eur. Urol 1999: 35:492-495	
	DT	Boyle Peter et al "Epidemiology of Prostate Cancer Chemoprevention" Eur Urol 1999: 35:370-376	
	DU	Hard, Gordon C. et al. "Major Difference in the Hepatocarcinogenicity and DNA Adduct Forming Ability between Toremifene and Tamoxifen in Female Crl: CD(BR) Rats" Cancer Research 53, 4534-4541, October 1, 1993	
	DV	Krieg, Michael et al "Androgens and Estrogens: Their Interaction with Stroma and Epithelium of Human Benign Prostatic Hyperplasia and Normal Prostate" J. Steroid Biochem. Vol. 19, No. 1 pp. 155-161, 1983	
	DW	Neubauer, et al (1995) "Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Prostate 27(4)220-9	
	DX	Nevalainen MT et al "Hormone regulation of human prostate in organ culture" Cancer Res. 1993 Nov 1:53 (21):5199-207	
	DY	Pylkanen, et al (1996) "Animal models for the preneoplastic lesions of the prostate" Eur. Urol. 30 (2) 243-8	
	DZ	Raghow, et al (2002) "Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model." Cancer Research 1;62(5) 1370-6.	
	EA	Steiner, et al (2001) Selective estrogen receptor modulators for the chemoprevention of prostate cancer." Urology 57(4 Suppl 1) 68-72	
	EB	Steiner, et al (2003) "Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk." World Journal of Urology 21(1) 31-6	
	EC	Zaridze, David G. et al "International Trends in Prostatic Cancer" Int. J. Cancer: 33, 223-230 (1984)	
BF	ED	Schneider, et al (1996) "Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity." 112 (3) 258-65	

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/747,686
				Filing Date	December 30, 2003
				First Named Inventor	STEINER, Mitchell S.
				Group Art Unit	1615
				Examiner Name	Fubara, Blessing M
Sheet	10	of	10	Attorney Docket Number	P-2769-US9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BF	EF	Schneider, et al (1991) "Effect of zindoxifene on experimental prostatic tumors of the rat." J. Cancer Res Clin Oncol. 117 (1) 33-6.	
BF	EG	Ip MM, et al (1980) "Funtionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma." Cancer Res 40 (7) 2188-93.	

Examiner Signature	/Blessing Fubara/	Date Considered	01/07/2007
--------------------	-------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.